Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Share-based Compensation (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Share-based Compensation for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 26.01% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.7 million, a 22.59% increase, with the full-year FY2025 number at $11.7 million, up 22.59% from a year prior.
  • Share-based Compensation was $2.0 million for Q4 2025 at TScan Therapeutics, down from $3.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.4 million in Q1 2025 to a low of $344000.0 in Q1 2021.
  • A 5-year average of $1.7 million and a median of $1.3 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 586.05% in 2021, then fell 26.01% in 2025.
  • TScan Therapeutics' Share-based Compensation stood at $784000.0 in 2021, then soared by 65.43% to $1.3 million in 2022, then grew by 15.65% to $1.5 million in 2023, then skyrocketed by 80.93% to $2.7 million in 2024, then dropped by 26.01% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Share-based Compensation are $2.0 million (Q4 2025), $3.0 million (Q3 2025), and $3.3 million (Q2 2025).